NCT06402721View on ClinicalTrials.gov

A Study to Learn About How BAY 3283142 Moves Into, Through, and Out of the Body After a Single Dose in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 17, 2024

Primary Completion Date

February 24, 2025

Study Completion Date

February 24, 2025

Conditions
Chronic Kidney DiseaseHepatic Impairment
Interventions
DRUG

BAY3283142

Single oral dose.

Trial Locations (1)

32809-3017

Orlando Clinical Research Center (OCRC), Orlando

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT06402721 - A Study to Learn About How BAY 3283142 Moves Into, Through, and Out of the Body After a Single Dose in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function | Biotech Hunter | Biotech Hunter